Clinical Trials Overview: mRNA Cancer Vaccines and Cell Therapies in China (2025)
China is rapidly becoming a global hub for next-generation cancer immunotherapy. With over a dozen active clinical trials for mRNA vaccines and immune cell therapies (TCR-T, CAR-T, adoptive cell therapy), Chinese oncology centers are offering access to cutting-edge treatments that are still years away from commercial availability in many Western countries.
If you or a loved one has been diagnosed with a solid tumor — particularly pancreatic cancer, KRAS-mutant cancers, or mesothelin-expressing malignancies — these trials may be worth exploring. Here’s a comprehensive overview of what’s currently available.
Important: This article is for informational purposes only and does not constitute medical advice. Always consult with your treating oncologist before making any treatment decisions. Trial availability changes frequently — contact our clinical trials team for the latest information.
Cell Therapies: Immune Cell Treatments for Advanced Tumors
Cell therapies involve modifying or activating a patient’s own immune cells to recognize and attack cancer. China has several active trials in this space, primarily for patients with advanced, metastatic disease who have exhausted conventional treatment options.
KRAS G12V-Targeted TCR-T Therapy
KRAS mutations are among the most common drivers in pancreatic cancer, lung cancer, and colorectal cancer. KRAS G12V, in particular, has been historically considered “undruggable” — until TCR-T (T-cell receptor-engineered T-cell) therapy entered clinical trials.
| Trial Phase | Therapy | Patient Eligibility | Center |
|---|---|---|---|
| Phase 1/2 | KRAS G12V-specific TCR-T | KRAS G12V mutant, HLA-A*11:01-positive advanced pancreatic cancer | Shanghai Changhai Hospital |
| Phase 1 | IX001 TCR-T | KRAS G12V mutant advanced pancreatic cancer | Sun Yat-sen University Cancer Center (Guangzhou) |
| Phase 1 | KRAS-specific autologous TCR-T | KRAS G12V mutant, HLA-A*11:01-positive advanced solid cancer | Beijing Ditan Hospital |
What international patients should know: TCR-T therapy requires HLA typing (specifically HLA-A*11:01 positivity) to determine eligibility. Molecular profiling of your tumor’s KRAS mutation status is essential before applying. Shanghai Changhai Hospital and Sun Yat-sen Cancer Center are among the most experienced centers in this space.
Other Cellular Therapies
| Trial Phase | Therapy | Patient Eligibility | Center |
|---|---|---|---|
| Phase 1 | CAR-T cells targeting Mesothelin | Mesothelin-expressing solid tumors | The Second Affiliated Hospital of Guangzhou Medical University |
| Phase 2 | SBRT + Adoptive Cell Therapy (vNKT cells) | Advanced pancreatic cancer | Shanghai Changhai Hospital |
Key difference: Unlike CAR-T therapies for blood cancers (which have achieved FDA approval), CAR-T for solid tumors remains experimental. The mesothelin-targeting trial in Guangzhou represents one of the few options for patients with solid tumors expressing this antigen. The vNKT cell therapy trial at Changhai Hospital combines radiation with adoptive immunotherapy — an approach designed to sensitize tumors before immune cell infusion.
Cancer Vaccines: mRNA and Neoantigen Approaches
Cancer vaccines work by training the immune system to recognize tumor-specific mutations (neoantigens). mRNA vaccines, in particular, have gained momentum since the COVID-19 pandemic demonstrated the platform’s speed and flexibility. China currently has multiple trials in this space, targeting both late-stage metastatic disease and post-surgical adjuvant settings.
mRNA & Neoantigen Vaccines for Late-Stage Metastatic Tumors
These trials target patients with chemotherapy-refractory advanced pancreatic cancer — typically those who have exhausted standard treatment options.
| Trial Phase | Therapy | Patient Eligibility | Center |
|---|---|---|---|
| Phase 1 | ABO2102 (KRAS neoantigen mRNA vaccine) | KRAS mutant advanced pancreatic cancer | Shanghai Ruijin Hospital |
| Phase 1 | mRNA-0217/S001 vaccine | Advanced pancreatic cancer | Shanghai Ruijin Hospital |
Context: ABO2102 is a personalized mRNA vaccine that targets KRAS neoantigens — specific mutations found only in the patient’s tumor. Shanghai Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, is a leading center for pancreatic cancer treatment in China and has been at the forefront of mRNA vaccine development.
mRNA & Neoantigen Vaccines as Adjuvant Therapy (Post-Surgical)
Post-surgical adjuvant therapy is where cancer vaccines show the most promise. After surgery removes the visible tumor, the immune system is better positioned to recognize and eliminate microscopic residual disease. This setting has produced the strongest clinical signals in pancreatic cancer vaccine research.
| Trial Phase | Therapy | Patient Eligibility | Center |
|---|---|---|---|
| Phase 1 | AK154 (mRNA vaccine) + mFOLFIRINOX chemo | Pancreatic cancer post-curative surgery | Fudan University Shanghai Cancer Center |
| Phase 1 | mRNA vaccine + PD-1 inhibitor | Pancreatic cancer post-curative surgery | Shanghai Ruijin Hospital |
| Phase 1 | Neoantigen vaccine + PD-1 + chemo | Pancreatic cancer post-curative surgery | West China Hospital, Sichuan University |
| Phase 1 | XP-004 (mRNA vaccine) + PD-1 | Pancreatic cancer post-curative surgery, chemo-intolerant | Shanghai Ruijin Hospital |
| Phase 1 | Personalized mRNA vaccine + Camrelizumab | Pancreatic cancer post-curative surgery | Nanjing Jinling Hospital |
| Phase 1 | XH001 (neoantigen vaccine) + ICI + chemo | Pancreatic cancer post-curative surgery | Peking Union Medical College Hospital |
Why adjuvant matters: Clinical evidence consistently shows that cancer vaccines are more effective in the adjuvant setting (after surgery, before recurrence) than in advanced disease. Reasons include:
- Lower tumor burden — fewer cancer cells for the immune system to target
- Less immunosuppressive microenvironment — intact tumors actively suppress immune responses; post-surgery, this suppression is reduced
- Better immune cell-to-tumor ratio — the immune system has a better chance of mounting an effective response
This means the optimal path for international patients considering vaccine trials is: complete standard treatment (surgery → adjuvant chemo) → enter a vaccine trial with no evidence of recurrence → monitor RFS/OS as primary endpoints.
What International Patients Should Do
Step 1: Get Molecular Profiling
Before exploring any immunotherapy trial, you need comprehensive molecular testing of your tumor:
- KRAS mutation type (G12D, G12V, G12C) — determines eligibility for TCR-T and neoantigen vaccine trials
- HLA typing (specifically HLA-A*11:01) — required for TCR-T eligibility
- Tumor mutational burden (TMB) — higher TMB correlates with better neoantigen vaccine response
- PD-L1 expression — relevant for trials combining vaccines with checkpoint inhibitors
Step 2: Complete Standard Treatment First
Vaccine trials in the adjuvant setting require completion of:
- Curative-intent surgery
- Standard adjuvant chemotherapy (typically 6 months of FOLFIRINOX or gemcitabine-based regimen)
- No radiographic evidence of disease
Step 3: Ask the Hard Questions
When evaluating any immunotherapy trial:
- What is the complete adverse event profile? Has ≥Grade 3 toxicity been reported?
- What are the actual RFS/OS data (not just immune response markers)?
- Is the trial actively recruiting, or is enrollment complete?
- What are the costs for international patients (trial drug, hospital fees, travel)?
Step 4: Consider a Medical Tourism Coordinator
Navigating Chinese clinical trials from abroad requires:
- Translation of medical records
- Understanding of Chinese regulatory requirements
- Visa and travel logistics
- On-the-ground coordination with hospital teams
This is where medical tourism services can add significant value — reducing friction and ensuring you’re matched with the right trial for your specific molecular profile.
Key Centers for Cancer Immunotherapy in China
| Center | Location | Specialties |
|---|---|---|
| Shanghai Ruijin Hospital | Shanghai | mRNA vaccines, KRAS-targeted therapy, pancreatic cancer |
| Shanghai Changhai Hospital | Shanghai | TCR-T therapy, adoptive cell therapy, pancreatic cancer |
| Fudan University Shanghai Cancer Center | Shanghai | mRNA vaccine + chemo combinations |
| Sun Yat-sen University Cancer Center | Guangzhou | TCR-T therapy for KRAS G12V |
| West China Hospital, Sichuan University | Chengdu | Neoantigen vaccines + checkpoint inhibitors |
| Peking Union Medical College Hospital | Beijing | Neoantigen vaccines + immunotherapy |
| Nanjing Jinling Hospital | Nanjing | Personalized mRNA vaccines |
The Bottom Line
China’s cancer immunotherapy landscape offers international patients access to treatments that are often 3–5 years ahead of what’s commercially available elsewhere. The most promising opportunities are:
- KRAS G12V TCR-T therapy — for patients with this specific mutation and HLA type
- Post-surgical mRNA vaccines — the strongest clinical signal in adjuvant pancreatic cancer
- Combination approaches — vaccines + checkpoint inhibitors + chemotherapy
The key is matching the right trial to the right patient. Molecular profiling is not optional — it’s the foundation of modern immunotherapy decision-making.
This article was compiled from publicly available clinical trial registrations, peer-reviewed publications, and hospital data. Trial availability changes frequently. For the latest information, contact our clinical trials team. Last updated: May 2025.
Source: Adapted from clinical trial summaries published by Dr. GHL (鹤医声), with additional context for international patients.